Drugs / Blink® Tears eye Drops
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05814367 | Apr → May 2023 | — | Johnson & Johnson Vision Care, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05661851 Comparator | Feb → Apr 2023 | dry eye syndrome | Johnson & Johnson Vision Care, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Blink Tears eye drops | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05814367 ↗ |
| Route | Topical | “receive 1-2 drops on each eye (right eye followed by left eye) over soft spherical contact lenses” NCT05814367 ↗ |